 |
 |
Amarin's President to Receive the 'Outstanding Achievement in Parkinson's Disease' Award From Parkinson's Institute Wednesday October 15, 9:03 am ET - Amarin Cited as a Leader in Drug Therapies for Parkinson's Disease - LONDON, Oct. 15 /PRNewswire-FirstCall/ -- Amarin Corporation (Nasdaq: AMRN - News) announced today that Michael Coffee, president and chief operating officer, will receive the Parkinson's Institute's Outstanding Achievement in Parkinson's Disease Award on Saturday evening, October 18, during the15th anniversary dinner of the Institute being held at The Fairmont Hotel, San Francisco. The Sunnyvale, California-based Parkinson's Institute is the leading independent organisation conducting both basic and clinical research in Parkinson's Disease as well as providing broad patient care. Its mission is to find the cause and cure for these disorders; to provide the best available medical care to patients with movement disorders, to investigate better treatment and diagnostic tools; and to develop prevention strategies. Parkinson's Disease is believed to affect as many as one million Americans. In naming Michael Coffee to receive the coveted award, Parkinson's Institute Director of Development Dr. Gary Thorud said: "We are especially pleased to honour Michael Coffee and Amarin for their important work in serving the needs of Parkinson's patients. They are the newest pharmaceutical firm to take up the challenge of a sector that has been largely overlooked by the big drug companies and we greatly value what they have been able to achieve in a relatively short time." Commenting on his selection by the Institute, Mr. Coffee said: "I am deeply grateful and encouraged by this recognition. We, at Amarin, appreciate the support of the Parkinson's Institute as we pursue the common goal of improving the pharmacologic treatment options to benefit patients with movement disorders." The Parkinson's Institute was founded in 1988 by J. William Langston, MD, now its CEO and then a faculty member at Stanford Medical School and Chief of Neurology at Valley Medical Center in San Jose, California. Universally acknowledged as one of the pre-eminent researchers in the field, he conducted the groundbreaking work that led to the development of a laboratory model of Parkinson's Disease that has significantly advanced research in the treatment of movement disorders. Dr. Langston is also the current Director of the Michael J. Fox Foundation Medical Research Committee. Michael Coffee joined Amarin in January, 2001 as president and director of Amarin Pharmaceuticals, Inc. based in San Francisco, and of Amarin Corporation plc, its parent company headquartered in London. Prior to joining Amarin, Mr. Coffee was president and chief operating officer of Elan Pharmaceuticals North America, and, earlier, president and COO of Athena Neurosciences, Inc. Previously, he also held management positions with a number of major pharmaceutical companies. Amarin Corporation plc is a specialty pharmaceutical company focused on neurology. The Company plans to become a leader in these therapeutic categories by providing innovative products and solutions that address significant unmet medical needs. Amarin has seven pharmaceutical products on the US market along with a development pipeline that includes two late-stage candidates: Zelapar(TM) (selegiline orally disintegrating tablets), for Parkinson's Disease and LAX-101, a proprietary compound for Huntington's Disease. For press releases and other corporate information, visit our website at http://www.amarincorp.com Statements in this press release that are not historical facts are forward-looking statements that involve risks and uncertainties which may cause the Company's actual results in future periods to be materially different from any performance suggested herein. Such risks and uncertainties include, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development and commercialisation, the impact of competitive products and patents, as well as other risks and uncertainties detailed from time to time in periodic reports. For more information, please refer to Amarin Corporation's Annual Report for 2002 on Form 20-F and its Form 6-Ks as filed with the U.S. Securities and Exchange Commission. The Company assumes no obligation to update information on its expectations. Source: Amarin Corporation SOURCE: PR Newswire / Yahoo News (press release) http://biz.yahoo.com/prnews/031015/lnw010_1.html * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn